Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mevidalen in Alzheimer's disease
jRCT2031240412Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised, double-blind trial of mevidalen in Alzheimer's disease (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in Integrated Alzheimer's Disease Rating Scale (iADRS). Started Dec 2024; status: recruiting.
02
Drugs
mevidalen
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031240412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240412.